TY - GEN
T1 - From carbohydrate to peptidomimetic inhibitors of galectins
AU - Mayo, Kevin H.
PY - 2012/12/18
Y1 - 2012/12/18
N2 - Although the roles that galectins play in controlling and mediating various biological processes is ever growing, only recently have galectins been accepted as valid therapeutic targets for clinical intervention. Because galectin inhibitors have therapeutic potential in many areas, e.g. as anti-inflammatory, anti-cancer, and even anti-HIV-1 agents, considerable efforts are being made by many laboratories to discover or design galectin antagonists. However, none are presently available for standard-of-care use in the clinic. To date, most galectin antagonists target the carbohydrate binding site, and as such are generally ß-galactoside-analogs and glycomimetics. Several peptide-based galectin inhibitors have also been reported, and one of these, calixarene-based peptidomimetic PTX008 that targets galectin-1, is presently in a phase I clinical trial. This review provides an overview of various galectin inhibitors reported to date.
AB - Although the roles that galectins play in controlling and mediating various biological processes is ever growing, only recently have galectins been accepted as valid therapeutic targets for clinical intervention. Because galectin inhibitors have therapeutic potential in many areas, e.g. as anti-inflammatory, anti-cancer, and even anti-HIV-1 agents, considerable efforts are being made by many laboratories to discover or design galectin antagonists. However, none are presently available for standard-of-care use in the clinic. To date, most galectin antagonists target the carbohydrate binding site, and as such are generally ß-galactoside-analogs and glycomimetics. Several peptide-based galectin inhibitors have also been reported, and one of these, calixarene-based peptidomimetic PTX008 that targets galectin-1, is presently in a phase I clinical trial. This review provides an overview of various galectin inhibitors reported to date.
KW - CRD
KW - Carbohydrate binding domain
KW - NMR
KW - Nuclear magnetic resonance spectroscopy
KW - RMSD
KW - Root mean square deviation
UR - http://www.scopus.com/inward/record.url?scp=84905262488&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84905262488&partnerID=8YFLogxK
U2 - 10.1021/bk-2012-1115.ch003
DO - 10.1021/bk-2012-1115.ch003
M3 - Conference contribution
AN - SCOPUS:84905262488
SN - 9780841228801
T3 - ACS Symposium Series
SP - 61
EP - 77
BT - Galectins and Disease Implications for Targeted Therapeutics
PB - American Chemical Society
ER -